Finasteride safety: the 2026 MHRA update and when to seek help

Clinician examining a man's scalp during a hair-loss assessment

The action to take matters more than an argument about risk

A new change in mood or sexual function while taking hair-loss medicine deserves care, not reassurance based only on an average from a trial. The UK Medicines and Healthcare products Regulatory Agency (MHRA) strengthened safety warnings for finasteride and dutasteride on 11 May 2026. Its advice gives different instructions for finasteride 1 mg, finasteride 5 mg and dutasteride. Knowing which medicine and strength you take is important.

If you have seriously harmed yourself or feel at risk of serious harm, call 999 immediately. A routine hair-loss consultation is not the right route for an immediate mental-health emergency.

What the MHRA updated in May 2026

The MHRA states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction, which may persist after treatment stops. The updated product information for finasteride 1 mg will explain that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported without mood changes.

For dutasteride, the MHRA recommended a precautionary warning because mood changes have been reported with another medicine in the same class, finasteride. The regulator describes the data for dutasteride as very limited. That distinction matters: a precautionary class warning is not the same as evidence that the two medicines have identical risks.

The UK finasteride patient cards, introduced in 2024, remain in place. They highlight psychiatric and sexual side effects and the action to take. This is a UK safety update, not simply a summary of advice from another country.

If you take finasteride 1 mg for hair loss

The MHRA advises stopping finasteride 1 mg immediately if depression or suicidal thoughts develop, and contacting your doctor as soon as possible. Do not wait for the next routine prescription or a hair-progress photograph review. If you cannot reach your usual clinician and need urgent mental-health help, use an appropriate urgent-care route rather than waiting for a non-urgent clinic response.

This advice is specific to these symptoms and this medicine. It is not a direction for everyone taking finasteride to stop treatment, nor an invitation to change other prescribed medicines without advice.

If you are unsure what you take, the packaging, dispensing label or pharmacist can establish the product and strength. Take that information into the conversation with the prescriber.

If you take finasteride 5 mg or dutasteride

The MHRA advises contacting your healthcare professional as soon as possible if depression or suicidal thoughts develop while taking finasteride 5 mg or dutasteride. Do not assume that an instruction written for the 1 mg hair-loss tablet applies unchanged to a different prescription.

Finasteride 5 mg and dutasteride are indicated for benign enlargement of the prostate. Some medicines are also used outside their licensed indication in hair-loss practice. The reason for your prescription and the exact product should be clear to the clinician reviewing a possible reaction. An article cannot safely replace that review.

Sexual side effects also warrant a conversation

The MHRA advises people taking finasteride or dutasteride to contact their healthcare professional if they experience decreased sex drive, erection difficulties or ejaculation problems. A change can be distressing in its own right, whether or not mood has also changed.

Sexual symptoms should not be dismissed because a trial found a low average rate, or because there are other possible causes. Equally, symptoms beginning during treatment do not by themselves prove a single cause. The clinician needs to consider the timing, other medicines, health conditions and the effect on wellbeing.

The regulator acknowledges that sexual dysfunction may persist after finasteride is stopped. This does not establish how often persistence occurs in a particular population or predict an individual's recovery. Avoiding an unsupported promise is part of taking a concern seriously.

Contact the clinic about a non-urgent treatment review. Contact your own prescriber directly about a possible medicine reaction; urgent symptoms should not wait for an enquiry reply.

What a careful review includes

The review should identify the medicine, strength, start date and any changes in dose or formulation. The clinician will want to know when symptoms began, whether they are continuing, and whether there is a history of depression or suicidal thoughts. Other prescribed medicines, supplements and non-prescription products may also be relevant.

The MHRA advises prescribers to ask about a history of depression or suicidal thoughts before treatment and to review regularly for psychiatric and sexual side effects. A family member or trusted person may sometimes notice changes that are difficult to recognise yourself. Sharing concerns with someone you trust can support timely help, while the medical assessment remains the clinician's responsibility.

Keep the leaflet and patient card supplied with your medicine. These are intended to remain available during treatment, not to be read only when a prescription starts.

Why safety reports are not a personal risk calculator

The MHRA's Yellow Card system collects suspected adverse-reaction reports. Such reports help identify and investigate safety signals. They do not by themselves establish that a medicine caused every reported event, and a count of reports cannot be divided by an unknown number of users to produce a reliable individual risk.

This is especially relevant when online discussions present alarming totals or use low trial percentages to dismiss all later reports. Trials, observational research and safety reporting answer different questions. The practical response to a new symptom is timely clinical assessment, not an argument about which kind of evidence cancels the others.

A hair-loss plan can be reconsidered without rushing into another treatment

After a suspected reaction, replacing one medicine with a procedure is not the immediate priority. The health concern needs appropriate care first. A later hair-loss review can revisit the diagnosis, goals and available options. It should not promise that PRP, topical treatment or any other approach will reproduce a medicine's benefits without trade-offs.

At The London PRP Clinic by The Wellness, enquiries about hair loss can begin with an assessment of the diagnosis and whether a proposed treatment is appropriate. View assessment appointment options, or contact the clinic about a non-urgent review. Immediate safety concerns belong with urgent care or the prescribing clinician, not a sales enquiry.

Common questions

Should everyone taking finasteride stop?

No. The MHRA gives specific action for symptoms. For finasteride 1 mg, depression or suicidal thoughts mean stop immediately and contact the doctor as soon as possible. Immediate danger requires emergency help.

Is the advice the same for finasteride 5 mg?

No. The MHRA advises contacting the healthcare professional as soon as possible if depression or suicidal thoughts develop with finasteride 5 mg or dutasteride. Check the exact medicine and strength rather than assuming.

Do sexual side effects matter if my mood is unchanged?

Yes. The MHRA advises contacting a healthcare professional about sexual dysfunction. It can occur without mood changes and deserves assessment in its own right.

Does the warning prove that every symptom is caused by the medicine?

No. A recognised safety concern is a reason to act appropriately, not proof of the cause of every individual symptom. Assessment should consider other explanations without dismissing the reported experience.

Is the patient card new in 2026?

No. UK finasteride patient cards were introduced in 2024. The May 2026 update retains them and strengthens product-information warnings.

Can PRP treat a medicine-related mood change?

No. PRP is not treatment for depression, suicidal thoughts or sexual dysfunction. Those concerns need appropriate medical care before elective hair treatment is considered.

Sources

This article provides general safety information, not an individual diagnosis. Read the leaflet supplied with your medicine and seek advice appropriate to the symptoms and urgency.

Previous
Previous

Bone bruise on a knee MRI: what marrow oedema means for recovery

Next
Next

Itchy scalp after minoxidil: irritation, allergy and the right next step